RESULTS: Overall, 971 (36%) patients underwent RARC and 1,705 (64%) ORC. RARC became the most commonly performed procedure in contemporary patients, with an increase from 14% in 2006-2007 to 58% in 2016-2018 (p<0.001). Patients who underwent RARC were younger than those treated with ORC (median 67 years CONCLUSIONS: The use of RARC is constantly increasing overtaking at these selected centers, ORC. In the last decade perioperative outcomes remained substantially unchanged. We confirmed the lower blood loss and shorter length of stay of RARC compared to ORC. Studies need to reveal whether these quality criteria translate into sustainable long-term quality and quantity of life benefits.
INTRODUCTION AND OBJECTIVES:
Concern has been raised about the oncologic soundness of robot-assisted radical cystectomy (RARC). We present our experience with disease recurrence and metastasis after RARC for bladder cancer.
METHODS: The City of Hope RARC database was queried to identify all patients who underwent RARC for primary urothelial carcinoma of the bladder between 2003 and 2015. Disease recurrences and metastases were categorized by location. The reverse Kaplan-Meier method was used to calculate time to recurrence-or metastasis-free (RMFS) and overall survival (OS). Log rank test was used to compare survival curves. Univariate and multivariate analysis were performed to identify predictors of RMFS and OS.
RESULTS: 379 patients fit the study criteria. The median follow up was 61 months. 97 patients (25.6%) developed recurrence or metastasis during the study period. The most common site of recurrence or metastasis was the pelvis (n[33), followed by the lungs (n[24), retroperitoneum (n[23), bone (n[19) , and liver (n[13). The most distant extent of disease in these patients was locoregional recurrence in 20 patients, retroperitoneal recurrence in 13 patients, distant metastasis in 54 patients, and peritoneal carcinomatosis in 10 patients. 11 of 379 (2.9%) patients had positive surgical margins. 12.4% of patients who did not develop recurrence or metastasis were nodepositive (35/282), compared to 44.3% (43/97) of patients who did develop recurrence or metastasis. 3 year RMFS for <pT2, pT2, pT3, and pT4 disease was 89.9%, 73.3%, 57.6%, and 36.5%, respectively (p<0.0001). 3 year OS for these stages was 86.7%, 61.5%, 40.1%, and 21.5%, respectively (p<0.0001). On multivariate analysis, pathologic T stage and pNþ disease predicted RMFS. American Society of Anesthesiologists score (ASA), pathologic T stage, and pNþ disease predicted OS.
CONCLUSIONS: RARC demonstrates acceptable RMFS and OS across disease stages. Pathologic T stage and pNþ disease predict RMFS and OS after RARC. ASA also predicts OS after RARC. METHODS: From July 2010 through December 2017, 277 consecutive patients who underwent robotic radical cystectomy (RRC) for bladder cancer at our institution were prospectively analysed. IRB approval was obtained (HS-01B014). Patients who simultaneously demonstrated negative soft tissue surgical margins, [/> 16 lymph node yield, absence of major (Clavien-Dindo grade III-IV) complications at 90 days, absence of urinary diversion (UD) related long-term sequelae and absence of clinical recurrence at [/< 12 mo. were considered as having achieved the RC-pentafecta. We created a multivariable logistic regression model using age, ASA score, type of UD, NACH, pT and pN stage as covariates to measure independent factors for achieving RC-pentafecta. The internal validity of the prediction model was assessed by 1,000 bootstrap samples with a two-tailed p-value less than 0.05 being statistically significant. (SPSS 24 Inc., Chicago, IL, USA).
RESULTS: Since 2010, 270 out of 277 patients that had completed at least 12mo. follow-up were included in this analysis. Over a median follow up of 39.5 months, [/> 16 lymph node yield, negative soft surgical margins, absence of major complications at 90 days and absence of UD-related surgical sequelae and clinical recurrence at [/< 12 months were observed in 93.0%, 98.9%, 76.7%, 81.5% and 92.2%, patients, respectively resulting in a RCpentafecta of 53.3% (Fig. a) . When comparing UD, IC was showed higher RC-pentafecta rate (Fig. B) (Fig. C) .
CONCLUSIONS: We present RC-pentafecta as a standardisable composite endpoint that incorporates peri-operative morbidity and oncologic adequacy as a potential tool to assess quality of radical cystectomy. This tool may be useful for assessing learning curve and calculating cost effectiveness amongst others but needs to be externally validated in future studies.
